Sanofi India Limited — Investor Meet, 04-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Sanofi India's Q3 shows double-digit growth and improved margins (29% net sales ratio from 23%), driven by strategic transformation and operational efficiency. The company is accelerating growth, with diabetes insulin and partnerships growing 5% QoQ. OPEX reduced 30%, partly due to INR 27 Cr restructuring for the Emcure partnership, which also supports legacy brands' reach. Exports declined as expected but with minimal profit impact, new markets are being explored. Management is confident in focusing on India's diabetes market, leveraging innovation like Soliqua and AI for efficiency and forecasting. Employee costs are down to INR 42 Cr, with further savings expected.